Currently, important precision molecular therapies in glioma include those targets involved in the regulation of recruitment, differentiation and activation of TAMs (CCL2, CCL3, CCL5, CCR5, IL-6, GM-CSF, CSF-1, VEGF and CXCL8); some of these molecules are already in the animal testing phase, such as CSF-1 (35). The gene discussed is CCL5; the disease is central nervous system cancer.